CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model.
| Author | |
|---|---|
| Abstract |
:
Osteosarcoma is the most common primary malignant bone tumor with a 5 year survival rate of up to 70%. However, patients with metastatic disease have still a very poor prognosis. Osteosarcoma metastasis models are essential to develop novel treatment strategies for advanced disease. |
| Year of Publication |
:
2017
|
| Journal |
:
Oncotarget
|
| Volume |
:
8
|
| Issue |
:
69
|
| Number of Pages |
:
114095-114108
|
| Date Published |
:
2017
|
| DOI |
:
10.18632/oncotarget.23125
|
| Short Title |
:
Oncotarget
|
| Download citation |
